All Posts

Trump floats new cannabis rules: Weeding out the good from the bad

Dec 15, 2025

•

11 min read

$3.2 Billion Raised This Week in the US Biotech Markets... Australia Next?

Dec 12, 2025

•

9 min read

Immuron’s Clinical Trial Faceplant: Bad News... But Not a Company Killer

Dec 11, 2025

•

9 min read

Imugene’s Phase 3 Pathway Is Clear - Its Funding Path Isn’t

Dec 10, 2025

•

9 min read

Immutep drops a US$370M deal... at 6:54pm

Dec 9, 2025

•

7 min read

A Tale of Two IPOs: Lessons From Saluda and Epiminder’s Tough Debuts

Dec 8, 2025

•

11 min read

Are AI-Predicted Clinical Trials the Future of Drug Development?

Dec 5, 2025

•

5 min read

The Moment Invion (IVX) Became “Investible” for me

Dec 4, 2025

•

7 min read

The Hidden Signals Found in AGM Updates

Dec 3, 2025

•

7 min read

Inside the Visionflex Lazarus Story

Dec 2, 2025

•

6 min read

What happens when a biotech stock goes up on "no news"...

Dec 1, 2025

•

5 min read

Biotech green shoots emerge in Australia and the US

Nov 28, 2025

•

4 min read

1...12 13 14 15

All Posts

Trump floats new cannabis rules: Weeding out the good from the bad

$3.2 Billion Raised This Week in the US Biotech Markets... Australia Next?

Immuron’s Clinical Trial Faceplant: Bad News... But Not a Company Killer

Imugene’s Phase 3 Pathway Is Clear - Its Funding Path Isn’t

Immutep drops a US$370M deal... at 6:54pm

A Tale of Two IPOs: Lessons From Saluda and Epiminder’s Tough Debuts

Are AI-Predicted Clinical Trials the Future of Drug Development?

The Moment Invion (IVX) Became “Investible” for me

The Hidden Signals Found in AGM Updates

Inside the Visionflex Lazarus Story

What happens when a biotech stock goes up on "no news"...

Biotech green shoots emerge in Australia and the US

The Armchair Analyst